Product Profile
Quantify previously undetected biomarkers – powered by Singulex
Uncover clinically relevant biomarkers faster and with more confidence than ever before
S
ingulex (
www.singulex.com) has pio- neered digital single-molecule count- ing (SMC) technology that can quan- titatively measure proteins and metabolites directly in complex biological samples. Proprietary digital detection technology and high precision immunoassays are com- bined in the Erenna® Immunoassay System to provide higher sensitivity and broader dynamic range over traditional immunoassay platforms. The Erenna System utilises a bead suspension sand- wich assay to directly capture the analyte, and the eluate is then read on a separate detection plate. This unique assay approach, along with Singulex’s propri- etary Sgx link™ software algorithm, pro- vides a lower background and increased slope, enabling quantification of low abundance biomarkers and monitoring of levels over time. Typical plate readers excite the bulk of a sample in a well and then attempt to measure the fluorescence in the entire well. This works well when the target concentration is high enough, but a deficiency arises at low concentra- tions, as the bulk sample has some intrin- sic emission, and thus the sample is lost in
the background. This inability to quantify low level samples makes it impossible to obtain baseline endogenous measurements or to stratify healthy and normal individu- als, which is critical for many study designs. In a direct comparison with a tra- ditional ELISA-based assay, Singulex sin- gle-molecule counting technology shows improved assay sensitivity. This head-to- head comparison demonstrates significant improvement in detection capabilities by migrating it to the Singulex high precision digital Erenna immunoassay platform. The flexible Singulex Solution includes the Erenna Immunoassay System with broad dynamic range of up to 4 logs, High- Definition Immunoassays with advanced precision and high-sensitivity, and a full range of Custom Services (Assay Development, Sample Testing and Antibody Derivatization). Flexibility is
High-definition Erenna Immunoassay System, powered by Singulex’s patented single-molecule detection technology enhances the clinical utility of biomarkers and allows researchers to gain insights into drug safety and efficacy
• Quantifying the previously undetectable. • Uncovering novel biology.
• Accelerating discovery. • Generating relevant data.
• Requiring fewer data points for critical decision making
• Reducing program costs and improving ROI.
1000 100 10 1
0.1 0.01
truly achieved with Assay Development kits enabling you to develop immunoassays specific for your research needs. Access the Singulex Solution to go from discovery to clinical trials – with more accuracy, relia- bility and confidence than ever before. Imagine seeing the unseen to accomplish breakthrough discoveries? With access to the Singulex Solution, you can go beyond imagination! See Data Now>> (@
www.singulex.com/imagine).
Drug Discovery World Spring 2013 17
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80